News in the Life Sciences Industry

TEL AVIV, Israel, May 13, 2019 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure... Read more ››

TEL AVIV, Israel, May 6, 2019 /CNW/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors... Read more ››

TEL AVIV, Israel, May 6, 2019 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure... Read more ››

SINGAPORE, April 26, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, has launched a new patient safety program for hospitals, called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME). Aimed at addressing the... Read more ››

SINGAPORE, April 25, 2019 /CNW/ -- The higher demand for services and improved quality of care has been attracting significant global investments to the Asia-Pacific healthcare industry.

SINGAPORE, April 15, 2019 /PRNewswire/ -- Tessa Therapeutics, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies targeting solid tumors, today announced that it has entered into an agreement with Merck (known as MSD outside the US and... Read more ››

SINGAPORE, April 8, 2019 /CNW/ -- AUM Biosciences has been honored with the 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year Award from Frost & Sullivan.

HONG KONG, SUZHOU, China and HANGZHOU, China, March 28, 2019 /PRNewswire/ -- Transcenta Holding (Transcenta) today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company (Lilly) to license a portfolio of novel biotherapeutics programs in... Read more ››